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Objectives: Ministry of Health, Labour and Welfare of Japan aims for the introduc-
tion of Health Technology Assessment in FY2016. Compared to foreign countries, a 
lack of resources for conducting the analysis has been pointed out in Japan. However, 
pharmaceutical and medical device industries are urged to seek practical approaches 
utilizing best available resources. The objective of this study was to review articles 
for cost-effectiveness analysis of major depression disease (MDD) and to evaluate 
analytical approaches that can be applied to Japanese environment. MethOds: The 
literature search was conducted in MEDLINE and JDream III. Inclusion criteria are 
studies of 1) treatment for MDD, 2) cost-effectiveness analysis (CEA), 3) published in 
the past 10 years. Studies were assessed for the followings: country, model structure 
and simulation method, time horizon, perspective, source of key parameters, results, 
and key drivers determined from sensitivity analysis. Results: Twenty-three stud-
ies were reviewed in details. Markov (6 articles) and decision-tree (8 articles) models 
were adopted, and time horizon were relatively short, ranging from 8 weeks to 5 
years. Thirteen studies included costs of productivity loss. Costs were based on lit-
erature or expert opinion in 21 studies. Utility scores were referred to other studies 
(17 articles). Parameters which became key drivers for these analyses varied among 
studies. cOnclusiOns: Data collection methods adopted in prior studies were con-
sidered applicable to CEA for UC treatment in Japan. Cost data can be obtained not 
only from questionnaire survey to doctors but commercial database. Because evidence 
on utility scores of Japanese population is still limited, further studies will be needed, 
especially on MDD patients in depression, remission, and relapse phase of treatment.
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Objectives: Patients with chronic schizophrenia are difficult to manage and costly 
to the health system. The European Medicines Agency has approved paliperidone 
palmitate (PP-LAI; Xeplion®), an atypical antipsychotic depot which is adminis-
tered monthly. However, its pharmacoeconomic profile in Portugal is unknown. 
Therefore, we conducted a cost-effectiveness analysis from the analytic viewpoint 
of the Portuguese National Health Service. MethOds: PP-LAI was compared with 
long acting injectable forms of risperidone (RIS-LAI) and haloperidol (HAL-LAI) as 
well as oral drugs (oral-OLZ) using a 1-year decision tree previously used in Europe 
and adapted to Portugal with guidance from clinical experts. We obtained clinical 
information and costs from literature sources and published lists. Clinical out-
comes included relapses (both requiring and not requiring hospitalization), days 
with relapse, and quality-adjusted life-years (QALYs). Costs were expressed in 
2015 euros. Economic outcomes included a cost-utility (incremental cost/QALY) 
and cost-effectiveness analyses (incremental cost/relapse as well as hospitalization 
avoided). Results: PP-LAI had the lowest rates for all negative events. Respective 
outcomes for PP-LAI, RIS-LAI, HAL-LAI and oral-OLZ included relapse days (37.4, 51.2, 
79.5, 78.0), Emergency Room visits (0.122, 0.168, 0.250, 0.242), hospitalizations (0.288, 
0.394, 0.623, 0.615) and QALYs (0.8227, 0.7985, 0.7585, 0.7609). Expected costs were 
lowest for oral-OLZ (4447€ ), followed by 4474€ for HAL-LAI, 5326€ for PP-LAI, and 
6223€ for RIS-LAI. HAL-LAI and RIS-LAI were both dominated and eliminated from 
further consideration. PP-LAI had an ICER of 14,247€ /QALY gained over oral-OLZ, 
which was considerably below the NICE threshold (≈27,600€ ). In cost-effectiveness 
analyses, PP-LAI had ICERs of 1902€ /relapse avoided and 2626€ /hospitalization 
avoided. Model drivers were hospitalization for HAL-LAI (74%) and oral-OLZ (59%); 
for PP-LAI 49% was due to drug and 39% hospitalization and for RIS-LAI it was 44% 
drug and 44% hospitalization. cOnclusiOns: PP-LAI is cost-effective in Portugal 
when compared with the customary treatments.
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Objectives: As a chronic illness, schizophrenia consumes a vast amount of health-
care resources and is therefore associated with both high direct and indirect health-
care costs. Pervasive suboptimal quality of life coupled with a high economic burden 
renders policy and healthcare decision makers seeking cost-effective treatments. This 
study aimed at evaluating the cost-effectiveness of aripiprazole once-monthly 400mg 
(AOM) versus paliperidone palmitate 50-150mg (PP) in the maintenance treatment 
of schizophrenia based on the QUALIFY study (NCT01795547). MethOds: QUALIFY 
was a 28-week, randomised, open-label, rater-blinded study comparing AOM with PP 
in the maintenance treatment of schizophrenia. Two key outcomes demonstrated 
improvements for AOM vs. PP: Heinrichs-Carpenter Quality of Life Scale (QLS) and 
Clinical Global Impression – Severity (CGI-S). To assess cost-effectiveness, minimal 
clinically important differences (MCIDs) were sought from the literature in the respec-
tive assessment scales. Treatment response was defined as a change from baseline to 
study termination of at least 6 points and 1 point on QLS total score and CGI-S score, 
respectively. Mean treatment specific costs (incl. drug acquisition) were estimated 
using QUALIFY healthcare resource utilisation data. The analysis was conducted from 
a UK perspective considering direct costs only. Results: In the deterministic analysis 
mean total costs per-patient were £2,093 and £2,954 for AOM and PP, respectively 
for people with moderate to severe conditions. The aim of this research was to 
estimate the costs of pharmaceuticals to the Australian public health sector and 
the most frequently prescribed drugs for the three most prevalent mental illnesses: 
depression, anxiety-related, and substance use disorders. MethOds: The National 
Survey of Mental Health and Wellbeing(NSMHWB) has been conducted every 10 
years since 1997, collecting epidemiology and economic impact to Australian soci-
ety. Respondents diagnosed within the preceding 12 months with depression (D), 
anxiety-related disorders (ANX), and substance use disorders (SUB) by ICD-10 in 
NSMHWB 2007 were included in the analysis. The NSMHWB 2007 reported the 
duration and the name of up to five drugs used during the past 12-month period. 
In order to adjust for inflation, 2013-14 reference year was adopted for the unit 
cost of each drug obtained from Pharmaceutical Benefit Scheme (PBS). Results:: 
Around 23% of respondents used medications for a total cost to the society of AUD 
101 million (SE 11.9). Citalopram was the most frequently prescribed drug (17.11%), 
followed by venlafaxine (15.65%), sertraline (14.43%), and temazepam (10.51%). 
Respondents reported with D+ANX+SUB had the highest percentage in use of 
medications (63.85%), followed by D+ANX (44.26%), and D (34.74%). ANX accounted 
for 50% of total medication costs followed by D+ANX at 23.6%. cOnclusiOns:: 
The high prevalence of ANX contributed to the large proportion of medication costs 
for this condition.
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Objectives: Aripiprazole once-monthly (AOM) is a long-acting injectable formula-
tion of aripiprazole, and is approved in Europe for the maintenance treatment of 
schizophrenia after stabilization with oral aripiprazole. The objective of this research 
was to evaluate the cost-effectiveness of AOM versus paliperidone palmitate (PP) in 
the maintenance treatment of schizophrenia in Spain. MethOds: This pharmaco-
economic evaluation was conducted alongside a 28-week, randomized, open-label, 
rater-blinded study comparing AOM 400mg and PP (50-150mg) in stabilized adults 
with schizophrenia. Effectiveness outcomes of the cost-effectiveness analyses (CEA) 
included the changes in Heinrichs-Carpenter Quality of Life Scale (QLS-primary CEA) 
and Clinical Global Impression-Severity (CGI-S) score at week 28. Visits with health-
care providers, out- and in-patient services were collected using a health economic 
assessment questionnaire (HEA). Healthcare services unit costs from the Basque 
Country were used (2014 costs). All patients with at least one valid post-baseline 
HEA were eligible for analysis. Bootstrapped confidence intervals were generated 
from 10,000 simulations, as well as cost-effectiveness acceptability curves. Results: 
Over the total 28-week period, AOM was associated with significantly reduced total 
healthcare costs compared to PP (mean per-patient cost: € 1,935 vs. € 2,475, respec-
tively; p< 0.001). This cost reduction was primarily due to significant reduction in drug 
acquisition costs (€ 1,237 vs. € 1,889; p< 0.001). The other cost aggregates (healthcare 
provider costs, out- and in-patient costs) were not statistically different between drugs 
(p= 0.528, p= 0.102 and p= 0.194, respectively). In the primary CEA, AOM dominated 
PP (being more effective on the QLS scale and less costly). This result was confirmed 
when using CGI-S as effectiveness measure. The cost-effectiveness acceptability 
curves indicated that AOM was the treatment of choice whatever willingness-to-pay 
threshold used. cOnclusiOns: Aripiprazole once-monthly was associated with 
statistically significantly reduced healthcare costs and greater effectiveness com-
pared to paliperidone palmitate in all scenarios, showing its economic value in the 
management of maintenance schizophrenia in Spain.
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Objectives: Information technology aided relapse prevention programme in 
schizophrenia (ITAREPS) is a unique mobile phone-based telemedicine solution 
for weekly remote patient monitoring and disease management of psychotic 
disorders in general, particularly of schizophrenia. RCTs evidence suggests that 
ITAREPS is highly effective in decreasing hospitalization schizophrenia relapses. 
Based on these RCTs, we performed a cost-utility analysis of ITAREPS compared to 
the treatment of schizophrenia without ITAREPS in the Czech Republic. MethOds: 
We developed a 20-year Markov cohort model with yearly cycle length and four 
health states, i.e. without relapse, with non-hospitalization relapse, with hospi-
talization relapse and death. Transition probabilities and resource use were derived 
from the Czech RCT and utilities were derived from published literature. Costs 
were calculated from healthcare payer’s perspective. Costs and outcomes were 
discounted by 3%. Probabilistic sensitivity analysis (PSA) with 3000 iterations was 
performed. Results: Over a 20-year time horizon, ITAREPS compared to non-
ITAREPS brings additional 0.21 QALY (12.33 vs. 12.12). The incremental total costs 
were -€ 5,554 (€ 55,435 vs. € 60,989) for ITAREPS. The insignificantly higher costs of 
ITAREPS service itself (€ 155 in the first and € 120 in subsequent years) are there-
fore vastly offset by savings of hospitalization relapse costs (€ 1,243 vs. € 11,748); 
ITAREPS on average prevents 5 hospitalization relapses in 20-year time horizon 
(0.73 vs. 5.77 hospitalizations) per patient. The results of the PSA show that ITAREPS 
is cost-effective in 93% iterations under the WTP threshold equal to € 0. An exten-
sive scenario analysis confirmed the base-case results, ITAREPS was dominant in 
all scenarios. cOnclusiOns: ITAREPS is a highly cost-effective intervention in 
patients with schizophrenia and it is even a dominant intervention in comparison 
with non-ITAREPS since it is more effective in terms of QALY gained and cheaper 
at the same time. There is even 93% probability of ITAREPS being cost-effective at 
the WTP threshold equal to € 0.
